Show simple item record

dc.contributor.authorCejalvo, Teresa 
dc.contributor.authorDel Portillo, Isabel
dc.contributor.authorLaborda, Eduardo
dc.contributor.authorVázquez, Fernando
dc.contributor.authorSardón, David
dc.contributor.authorRamirez, Manuel
dc.contributor.authorAlemany, Ramón
dc.contributor.authorDel Castillo, Noemí
dc.contributor.authorPerise-Barrios, Ana Judith 
dc.contributor.authorRodriguez-Milla, Miguel A 
dc.contributor.authorCubillo, Isabel 
dc.contributor.authorGarcia-Castro, Javier
dc.identifier.citationCancer Res. 2018 Sep 1;78(17):4891-4901.es_ES
dc.description.abstractDogs with spontaneous tumors treated in veterinary hospitals offer an excellent opportunity for studying immunotherapies, including oncolytic viruses. Oncolytic viruses have advanced into the clinic as an intratumorally administered therapeutic; however, intravenous delivery has been hindered by neutralization in the blood. To circumvent this hurdle, mesenchymal stem cells have been used as a "Trojan horse." Here, we present the treatment of 27 canine patients with cancer with canine mesenchymal stem cells infected with ICOCAV17, a canine oncolytic adenovirus. No significant adverse effects were found. The response rate was 74%, with 14.8% showing complete responses, including total remissions of lung metastasis. We detected virus infection, stromal degeneration, and immune cell infiltration in tumor biopsies after 4 weeks of treatment. The increased presence of antiadenoviral antibodies in the peripheral blood of treated dogs did not appear to prevent the clinical benefit of this therapy. These data indicate that oncolytic viruses loaded in mesenchymal stem cells represent an effective cancer immunotherapy.Significance: The classical clinical limitations of antitumoral viroimmunotherapy can be overcome by use of mesenchymal stem cells.Graphical Abstract: Cancer Res; 78(17); 4891-901. ©2018 AACR.es_ES
dc.description.sponsorshipWe want to thank the staff of Veterinary Hospital, the technical staff from the Anatomo-pathological Department, as well as Carolina Jiménez and Giulia Setti for their participation in our studies. We are grateful to A. Gómez Vitores for useful advice on the pathology studies. J. Garcia-Castro was awarded grants from the Fondo de Investigaciones Sanitarias (FIS: PI11/00377, PI17CIII/00013, RD12/0036/0027), the Madrid Regional Government (CellCAM; P2010/BMD-2420), and the Asociación Pablo Ugarte (G86121019). The experiments were approved by the appropriate committees. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.es_ES
dc.publisherAmerican Association for Cancer Research (AACR) es_ES
dc.subject.meshOncolytic Virotherapy es_ES
dc.subject.meshAnimals es_ES
dc.subject.meshDog Diseases es_ES
dc.subject.meshDogs es_ES
dc.subject.meshHumans es_ES
dc.subject.meshImmunotherapy es_ES
dc.subject.meshMesenchymal Stem Cells es_ES
dc.subject.meshNeoplasms es_ES
dc.subject.meshOncolytic Viruses es_ES
dc.titleRemission of Spontaneous Canine Tumors after Systemic Cellular Viroimmunotherapyes_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderComunidad de Madrid 
dc.identifier.journalCancer researches_ES
dc.repisalud.centroISCIII::Instituto de Investigación de Enfermedades Rarases_ES
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional